Corindus Vascular Robotics has announced that Aquilla “Quill” Turk has joined the company as chief medical officer, Neuroendovascular. Turk is a practicing physician at the Medical University of South Carolina, USA, where he serves as director of the Stroke and Cerebrovascular Program, director of the Neuroendovascular Program, and professor with a joint appointment in the Departments of Radiology and Neurosurgery. Turk will serve alongside Aaron Grantham, Corindus’ Cardiovascular CMO, to spearhead the company’s clinical initiatives and expand robotic treatment into neurovascular procedures, specifically targeting acute ischaemic stroke.
“I am pleased to welcome Turk to the Corindus team. His guidance and expertise will be critical as we expand our focus and technology to include treatment for neurovascular interventions,” stated Mark Toland, president and chief executive officer of Corindus. “We strongly believe that our technology pipeline can add value across the spectrum of vascular interventions, with remote access and advanced robotic capabilities at the forefront of our strategy.”
In addition to Turk’s appointment, Corindus has established a Physician Steering Committee dedicated to Neuroendovascular Procedures, which will be led by Turk. Members include:
- Ricardo A Hanel, Baptist Health System, Jacksonville, FL
- Tudor G Jovin, University of Pittsburgh Medical Center, Pittsburgh, PA
- Mocco, The Mount Sinai Hospital, New York, NY
- Raul G Nogueira, Grady Memorial Hospital, Atlanta, GA
- Vitor Mendes Pereira, MSc, Toronto Western Hospital-University Health Network, Toronto, ON
- Adnan Siddiqui, Toshiba Stroke & Vascular Research Center, UB, Buffalo, NY
- Satoshi Tateshima, Ronald Reagan UCLA Medical Center, Santa Monica, CA
- Raymond D Turner, Medical University of South Carolina, Charleston, SC
“I look forward to partnering with the Corindus team and the company’s Neuroendovascular Steering Committee to bring robotic treatment to neurovascular care,” said Turk. “I believe that robotics will be critical to transforming the treatment paradigm for the neurovascular space. Speeding up treatment time through remote access capabilities and robotic precision will revolutionise how patients with illnesses such as acute stroke receive treatment.”
